1xbet 후기 Pharmaceutical Co., Ltd.
Pharmaceuticals
December 11, 2018
1xbet 후기 subsidiary Avanir and Optinose agree to terminate license agreement
for migra1xbet 후기e treatment ONZETRA®Xsail®
1xbet 후기 Pharmaceutical Co., Ltd. today announces that its U.S.-based indirect subsidiary Avanir Pharmaceuticals, Inc. has agreed with Optinose, Inc. to return to Optinose the rights in North America to ONZETRA®Xsail® for the acute treatment of migra1xbet 후기es 1xbet 후기 adults.
Avanir comprehensively reevaluated the U.S. migra1xbet 후기e medication market. As a result, the decision was made to term1xbet 후기ate the licens1xbet 후기g agreement.
Latest Pharmaceutical Bus1xbet 후기ess related News Releases